Pharmaceutical major Cipla reported a 3 per cent year-on-year decline in March quarter revenue to Rs 6,541 crore, with net profit falling 55 per cent to Rs 554.6 crore, missing consensus estimates. Despite strong growth in India and Africa, a significant decline in North American sales impacted overall performance, with the company now focusing on new product launches and regulatory filings to drive future gains.
Sinha, who pioneered and popularised the rich folk traditions of Bihar beyond its borders, was undergoing treatment at All India Institute of Medical Sciences-Delhi for multiple myeloma, a form of blood cancer.
Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after analysts remained cautious on the company's Q3 performance and differed on its growth outlook. DRL's Q3 performance was viewed as subdued by some analysts when they adjusted it for one-time grants and incomes that the company received during the quarter.
'The great singer Shardaji took Bhojpuri music and singing to the national and international level with her singing!'
The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.
The 37-actress actress speaks about her cancer, films and why over the top Bollywood films are not for her.
An acute drug shortage in the US and stable pricing along with product launches are likely to boost revenues of India's pharmaceutical companies during the first quarter of this financial year, analysts said. Most brokerages estimate a top line growth of around 14-15 per cent, with earnings before interest, taxes, depreciation, and amortisation (Ebitda) growth of 24-30 per cent for Q1 of FY24. Hospitals are, however, likely to report lower occupancy rates, and diagnostics companies may witness an impact from delayed monsoon.
Bolstered by an impressive performance in the global specialty business and outstanding results in the Indian market, Sun Pharmaceutical Industries, the largest pharmaceutical (pharma) company in the country, showcased a strong performance in the July-September quarter (second quarter, or Q2) of 2023-24 (FY24).
Movie stars are not only madly in love in...well, the movies, but also in their real lives!
Bollywood is going through tough times as two beloved performers are unwell.
India's largest listed pharmaceutical (pharma) company - Sun Pharmaceutical Industries (Sun Pharma) - is expected to maintain its outperformance vis--vis the sector's, as its multiple bets on specialty products, improving product mix, recent acquisitions, and branded business are finding favour with brokerages. While it has gained 7 per cent over the past year, the Nifty Pharma Index is down 13.6 per cent. Its outperformance over two years has been fairly evident, with the market leader gaining 66 per cent to Nifty Pharma's minus 1.4 per cent.
The Canadian model and actress who was in Mumbai to inaugurate a cancer institute says she's glad she spoke out about her condition.
Salman finds 'jannat'... Rasika is tempted... Kartik plays with Katori...
Her finace Jason Dehni is the vice president of the Scotiabank Group.
'Luminous souls Sufi and Soleil are expanding us in ways we never thought possible.'
Dressed in an off-shoulder figure-hugging grey dress, Lisa Ray would have seemed like an unlikely face at a cancer institute. Ray who has recovered from multiple myeloma flew down from her hometown in Toronto, to launch Fortis Hospitals' cancer institute in Mumbai's eastern suburb of Mulund.
The actress is suffering from a rare and incurable cancer of the white blood cells.
'As his close associate Som Pal told me, "Mandal was never V P Singh's brainchild. It was a Janata Party commitment he inherited".' 'He would have done it anyway at some point, but the specific timing of his decision was dictated entirely by political exigency -- his government was threatened.' 'It also turned out to be a game changer in Indian politics.'
Designer Premal Badiani put the cause in the New York Fashion Week spotlight.
'If everybody knows your name, that's success. Isn't that what society tells us? I experienced all that at a very young age. So how come I wasn't happy?' Lisa Ray wonders.
